Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26685313 | 0.78 | NQO2 (0.32) | — | |
| SCHEMBL27053770 | 0.70 | NQO2 (0.31) | — | |
| SCHEMBL26781244 | 0.70 | — | — | |
| SCHEMBL10572748 | 0.67 | POLB (0.32) | POLBGAAKMT2A | |
| 5-Bromouracil SCHEMBL8740942 | 0.66 | — | — | |
| 5-Bromouracil SCHEMBL30790330 | 0.66 | — | — | |
| SCHEMBL30648909 | 0.64 | PTGER4 (0.32) | POLBGAAKMT2A | |
| SCHEMBL26640729 | 0.64 | PTGER4 (0.32) | POLBGAAKMT2A | |
| SCHEMBL2727243 | 0.64 | DYRK1A (0.36) | KMT2A | |
| SCHEMBL22208112 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276968-A1 | 8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BETA PHARMA, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4522614-A1 | 8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | Beta Pharma, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119156387-A | 8-Substituted and 6-substituted pyridopyrimidine derivatives as KRAS inhibitors | 贝达医药公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2023219941-A1 | 8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BETA PHARMA, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023219941-A1 | 8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BETA PHARMA, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276968-A1 | 8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | POLB 837/4885GAA 1307/4885KMT2A 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.